TY - JOUR
T1 - Hybrid Graphene-Gold Nanoparticle-Based Nucleic Acid Conjugates for Cancer-Specific Multimodal Imaging and Combined Therapeutics
AU - Yang, Letao
AU - Kim, Tae Hyung
AU - Cho, Hyeon Yeol
AU - Luo, Jeffrey
AU - Lee, Jong Min
AU - Chueng, Sy Tsong Dean
AU - Hou, Yannan
AU - Yin, Perry To Tien
AU - Han, Jiyou
AU - Kim, Jong Hoon
AU - Chung, Bong Geun
AU - Choi, Jeong Woo
AU - Lee, Ki Bum
N1 - Funding Information:
This work was partially supported by NSF (No. CHE‐1429062, CBET‐1803517), the New Jersey Commission on Spinal Cord Research (Nos. CSCR17IRG010 and CSCR16ERG019), NIH R21 (No. R21AR071101), and NIH R01 (Nos. 1R01DC016612, 3R01DC016612‐01S1, and 5R01DC016612‐02S1). All animals were acclimatized to the animal facility for at least 48 hours before experimentation and maintained according to the Guide for the Care and Use of Laboratory Animals published by the NIH. The animal protocol was approved by the Institutional review board of the Korea University (protocol number:1040548‐KU‐IRB‐13‐9‐A‐1).
Funding Information:
This work was partially supported by NSF (No. CHE-1429062, CBET-1803517), the New Jersey Commission on Spinal Cord Research (Nos. CSCR17IRG010 and CSCR16ERG019), NIH R21 (No. R21AR071101), and NIH R01 (Nos. 1R01DC016612, 3R01DC016612-01S1, and 5R01DC016612-02S1). All animals were acclimatized to the animal facility for at least 48 hours before experimentation and maintained according to the Guide for the Care and Use of Laboratory Animals published by the NIH. The animal protocol was approved by the Institutional review board of the Korea University (protocol number:1040548-KU-IRB-13-9-A-1).
PY - 2021/1/27
Y1 - 2021/1/27
N2 - Nanoparticle-based nucleic acid conjugates (NP-NACs) hold great promise for theragnostic applications. However, several limitations have hindered the realization of their full potential in the clinical treatment of cancer and other diseases. In diagnoses, NP-NACs suffer from low signal-to-noise ratios, while the efficiency of NP-NACs-mediated cancer therapies has been limited by the adaptation of alternative prosurvival pathways in cancer cells. The recent emergence of personalized and precision medicine has outlined the importance of having both accurate diagnosis and efficient therapeutics in a single platform. As such, the controlled assembly of hybrid graphene oxide/gold nanoparticle (Au@GO NP)-based cancer-specific NACs (Au@GO NP-NACs) for multimodal imaging and combined therapeutics is reported. The developed Au@GO NP-NACs show excellent surface-enhanced Raman scattering (SERS)-mediated live-cell cancer detection and multimodal synergistic cancer therapy through the use of photothermal, genetic, and chemotherapeutic strategies. Synergistic and selective killing of cancer cells are then demonstrated using in vitro microfluidic models. Moreover, with the distinctive advantages of the Au@GO NP-NACs for cancer theragnostics, precision cancer treatment through the detection of cancer cells in vivo using SERS followed by efficient ablation of tumors is shown. Therefore, the Au@GO NP-NACs can pave a new road for advanced disease theragnostics.
AB - Nanoparticle-based nucleic acid conjugates (NP-NACs) hold great promise for theragnostic applications. However, several limitations have hindered the realization of their full potential in the clinical treatment of cancer and other diseases. In diagnoses, NP-NACs suffer from low signal-to-noise ratios, while the efficiency of NP-NACs-mediated cancer therapies has been limited by the adaptation of alternative prosurvival pathways in cancer cells. The recent emergence of personalized and precision medicine has outlined the importance of having both accurate diagnosis and efficient therapeutics in a single platform. As such, the controlled assembly of hybrid graphene oxide/gold nanoparticle (Au@GO NP)-based cancer-specific NACs (Au@GO NP-NACs) for multimodal imaging and combined therapeutics is reported. The developed Au@GO NP-NACs show excellent surface-enhanced Raman scattering (SERS)-mediated live-cell cancer detection and multimodal synergistic cancer therapy through the use of photothermal, genetic, and chemotherapeutic strategies. Synergistic and selective killing of cancer cells are then demonstrated using in vitro microfluidic models. Moreover, with the distinctive advantages of the Au@GO NP-NACs for cancer theragnostics, precision cancer treatment through the detection of cancer cells in vivo using SERS followed by efficient ablation of tumors is shown. Therefore, the Au@GO NP-NACs can pave a new road for advanced disease theragnostics.
KW - graphene hybrid nanomaterials
KW - multimodal cancer theragnostics
KW - nanomedicine
KW - nanoparticle-based nucleic acid conjugates
KW - personalized medicine
UR - http://www.scopus.com/inward/record.url?scp=85093511960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093511960&partnerID=8YFLogxK
U2 - 10.1002/adfm.202006918
DO - 10.1002/adfm.202006918
M3 - Article
AN - SCOPUS:85093511960
VL - 31
JO - Advanced Functional Materials
JF - Advanced Functional Materials
SN - 1616-301X
IS - 5
M1 - 2006918
ER -